Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | LABP |
---|---|---|
09:32 ET | 192 | 21.9 |
09:56 ET | 100 | 21.9596 |
10:15 ET | 195 | 21.9216 |
12:25 ET | 100 | 22.055 |
03:38 ET | 7760 | 22.1501 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Landos Biopharma Inc | 68.5M | -6.3x | --- |
Anebulo Pharmaceuticals Inc | 69.5M | -6.6x | --- |
Instil Bio Inc | 69.7M | -0.4x | --- |
Rallybio Corp | 66.9M | -0.9x | --- |
Passage Bio Inc | 70.2M | -0.7x | --- |
AN2 Therapeutics Inc | 70.3M | -0.8x | --- |
Landos Biopharma, Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of novel, oral, once-daily therapeutics for patients with autoimmune diseases. It is engaged in the development of therapeutics that target novel pathways at the interface of immunity and metabolism. Its lead product candidate is NX-13, a novel, oral, gut-selective, NLRX1 agonist. It is developing NX-13 as a once-daily, oral treatment for ulcerative colitis (UC), and Crohn's disease (CD), that targets NOD-like receptor X1 (NLRX1), a mitochondria-associated receptor that has been associated with the modulation of inflammatory cytokines for UC and CD. NX-13 is designed to target NLRX1 and induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. It has several preclinical product candidates, including LABP-66, LABP-73 and LABP-69. LABP-73, an oral, small molecule NLRX1 agonist for the potential treatment of asthma and eosinophilic disorders.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $68.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 3.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.49 |
Book Value | $10.20 |
P/E Ratio | -6.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.